|
新闻
Sagent Pharmaceuticals Inc. Completes $53M Series A Financing
Schaumburg,
IL - September 27, 2007 Sagent Pharmaceuticals, Inc., a
privately-held specialty pharmaceutical company today announced the
closing of a $53 million Series A financing led by Vivo Ventures.
Proceeds from the financing will be used primarily to fund near-term
product launches, product development activities and strategic business
initiatives, including numerous development, sales and marketing,
manufacturing and distribution partnerships. "We appreciate Vivo
Ventures' continued commitment to Sagent's long-term growth," said
Jeffrey M. Yordon, CEO, founder and chairman of the board of Sagent
Pharmaceuticals. "This venture funding enables us to quickly advance
many of our recent development efforts into near-term commercialization
while accelerating development of our extensive pipeline. We are
confident that our strong financial position and experienced management
team, combined with the extensive experience and capabilities of our
business partners, positions us to achieve rapid success in our target
specialty product market."
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, founded in 2006, is a privately held specialty
pharmaceutical company focused on developing, manufacturing, sourcing
and marketing pharmaceutical products, with a specific focus on
injectable products. Sagent has created a unique, global network of
resources, comprised of rapid development capabilities, sophisticated
manufacturing and innovative drug-delivery technologies, quickly
yielding an extensive portfolio of pharmaceutical products that fulfills
the evolving needs of patients. Sagent currently has more than 200
products in development. For more information about the company and its
products, please visit
www.sagentpharma.com.
« 回 新闻
|
